Plasma Resilience: Europe's Lifeline
When considering medical breakthroughs, human plasma is often overlooked. However, this protein-rich liquid, making up 55% of our blood, is crucial for developing therapies for various conditions, including rare inherited disorders and immunodeficiencies.
Europe's supply chain for this valuable resource is extremely vulnerable, as plasma is uniquely human and cannot be produced in a lab. Instead, it relies on the generosity of donors, with over 12 million people across Europe donating plasma annually through a process governed by rigorous safety standards.
- EU Member States' safety standards
- International Quality Plasma Program (IQPP)
- Plasma Protein Therapeutics Association (PPTA) oversight
Despite these efforts, nearly 40% of plasma used to make medicines for Europe must be imported from the United States, highlighting the need to strengthen the continent's plasma resilience.
Each year, more than 12 million people across Europe donate plasma through a process governed by rigorous safety standards.
Author's summary: Europe's plasma supply chain is vulnerable and needs strengthening.
More News
- COLUMN: Bahamas getting the US Ambassador we need
- Universities Unveil Blueprint to Build a 'Stronger, Fairer Wales'
- Pope Leo appoints Cardinal Cupich to Vatican City State commission
- Brendan Gallagher: No-one is immune to this awful disease
- From Ballot To Bloodline: The Silent Coup Of Dynastic Politics In India
- Bob Ross paintings to hit auction block as fundraiser for APT’s Create
- TVA faces nuclear outage crisis - Nuclear Engineering International
- Summit Carbon Solutions looking at other options for pipeline route
- No. 11 Arkansas soccer looking to rebound vs. Alabama: What to know, how to watch | Whole Hog Sports
- Jackie Young Reflects on Aces' Third WNBA Championship, Celebrates With Raising Cane’s 'Shift' on the Strip